TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32995919

Group type: EXPERIMENTAL
Intervention: Standard IV intermittent bolus paracetamol therapy (15-mg/kg doses as 1-h infusions every 6 h for 5 days)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous IV paracetamol infusion therapy (60-mg/kg/day continuously for 5 days)
Number of subjects: 137
Study: 32995944

Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pridopidine 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pridopidine doses ranging from 22.5 to 90 mg
Number of subjects: 0
Study: 32996064

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Meropenem 1 g
Number of subjects: 100
Study: 32996096

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 80 U subcutaneously every other day to week 4, then twice weekly to week 24
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 32996164

Group type: EXPERIMENTAL
Intervention: CAC (+) group (34 patients diagnosed with CAC)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: CAC (-) group (1,067 patients without CAC)
Number of subjects: 1101
Study: 32996891

Group type: EXPERIMENTAL
Intervention: Phone calls (maximum of 3 calls on different days and times)
Number of subjects: 200
Study: 32997124

Group type: EXPERIMENTAL
Intervention: NCCN guidelines-based decision support tool
Number of subjects: 76
Study: 32997260

Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation (EMV) via face-mask or endotracheal intubation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation (EMV)
Number of subjects: 50
Study: 32997632

Group type: EXPERIMENTAL
Intervention: BCI-guided robot-assisted upper-limb training
Number of subjects: 14
Study: 32997657

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 26703

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients aged ≥85 years
Number of subjects: 26703

Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 26703
Study: 32997689

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neopterin (NP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CRP/NP ratio
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SAA/NP ratio
Number of subjects: 200
Study: 32998542

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ICD-related complications
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 165
Study: 32998750

Group type: EXPERIMENTAL
Intervention: Implementation strategies with clinician champions and organizational support
Number of subjects: 12

Group type: COMPARATOR
Intervention: No champion with necessary characteristics and/or organizational support
Number of subjects: 12
Study: 32998751

Group type: EXPERIMENTAL
Intervention: FGF-23 above the median
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Use of GLP-1 analogues
Number of subjects: 246
Study: 32998925

Group type: EXPERIMENTAL
Intervention: Management of sleep apnoea syndrome (SAS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SAS management parameters and questionnaires
Number of subjects: 60
Study: 32998963

Group type: EXPERIMENTAL
Intervention: Itacitinib (INCB039110), a JAK1 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32998965

Group type: EXPERIMENTAL
Intervention: Alvocidib (30 mg/m²) followed by 7+3 (Cytarabine 100 mg/m² + Daunorubicin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alvocidib (30 mg/m²)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7+3 (Cytarabine + Daunorubicin)
Number of subjects: 0
Study: 32999432

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study: 32999466

Group type: EXPERIMENTAL
Intervention: F-18-PSMA-1007-PET
Number of subjects: 53

Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 53

Group type: COMPARATOR
Intervention: Histopathology
Number of subjects: 53
Study: 33000389

Group type: EXPERIMENTAL
Intervention: ROTEM testing in Child-Pugh-C patients
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: ROTEM testing in compensated Child-Pugh-A patients
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: ROTEM parameters in patients with short CFT and high MCF in EXTEM
Number of subjects: 159
Study: 33000470

Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blockers (CCBs)
Number of subjects: 1459
Study: 33000661

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with identified risk factors
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Cardiac related reason for endotracheal intubation
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Pre-intubation noninvasive ventilation
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Emergency intubation
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Moderate-severe difficult bag-mask ventilation
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Crystalloid administration within the preceding 24 hours
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Higher baseline oxygenation
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Peri-intubation hypoxemia
Number of subjects: 1033
Study: 33000670

Group type: EXPERIMENTAL
Intervention: Fruit sources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegetable sources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 33001035

Group type: EXPERIMENTAL
Intervention: Wearable sleep EEG device (Zmachine Insight+, General Sleep Corporation)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Wearable sleep EEG device
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Wristworn actigraph
Number of subjects: 104
Study: 33001241

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with simultaneous integrated boost (SIB)
Number of subjects: 143
Study: 33001310

Group type: EXPERIMENTAL
Intervention: MGMT methylation in patients with moderately vascularized tumors (rCBV < 10.73)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MGMT methylation in patients with highly vascularized tumors (rCBV > 10.73)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MRI perfusion markers
Number of subjects: 96
Study: 33001538

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 62
Study: 33001549

Group type: EXPERIMENTAL
Intervention: Bilateral dorsolateral prefrontal cortex (DLPFC) theta burst stimulation (TBS) treatment for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group of age-matched healthy youths, N=16
Number of subjects: 16
Study: 33001967

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies (detected via lateral flow immunoassay test)
Number of subjects: 590
Study: 33002543

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) every 3 weeks for 4 doses followed by Nivolumab monotherapy (480 mg) every 4 weeks until progression or up to 1 year after consolidative thoracic radiation therapy (30 Gy in 10 fractions).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) with thoracic radiation therapy after platinum chemotherapy.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ipilimumab and Nivolumab treatment.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Increased cytotoxic T cell (CD3+CD8+) tumor infiltration.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reduction in peripheral blood CD3+CD8+ from baseline to after first dose of IPI/NIVO.
Number of subjects: 21
Study: 33002925

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by Mini-Cog; OR = 1.57; 95% CI, 0.70-3.53; corrected P value >.999
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by Mini-Mental State Examination; OR = 2.75; 95% CI, 1.23-6.13; corrected P value = .052
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive performance assessed by animal verbal fluency test; OR = 1.24; 95% CI, 0.49-3.16; corrected P value >.999
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Lower preoperative Scto2; OR = 1.08; 95% CI, 1.02-1.14; corrected P value = .024 for each point decrease in Scto2
Number of subjects: 238
Study: 33003016

Group type: EXPERIMENTAL
Intervention: Proportion of MAP values ≥85 mm Hg (average 75%)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Vasopressor use to elevate MAP
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Neurologic improvement measured by ASIA impairment scale
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Proportion of elevated MAP values
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Vasopressor dose
Number of subjects: 136
Study: 33003107

Group type: EXPERIMENTAL
Intervention: IL-5 intervention in an animal model of widespread muscle pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels of IL-5 secretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower percentage of intermediate monocytes (CD14++/CD16+)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater percentage of nonclassical monocytes (CD14+/CD16++)
Number of subjects: 0
Study: 33003873

Group type: EXPERIMENTAL
Intervention: Cough sound model
Number of subjects: 2362

Group type: EXPERIMENTAL
Intervention: Vocalised /ɑ:/ model
Number of subjects: 2362
Study: 33004046

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT) with a total irradiation dose of 48 Gy (RBE) delivered in twelve fractions; concurrent chemotherapy accepted if indicated.
Number of subjects: 25
Study: 33004078

Group type: EXPERIMENTAL
Intervention: Higher land use mix-access
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Existence of many alternative routes in the neighborhood
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Slow speed of traffic
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Few drivers exceeding the speed limits
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Higher levels of land use mix-diversity, better aesthetics, greater safety from crime, presence of crosswalks and pedestrian signals, greater proximity of shopping centers
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Higher land use mix-diversity
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: More walking/cycling facilities
Number of subjects: 8185

Group type: EXPERIMENTAL
Intervention: Better aesthetics
Number of subjects: 8185
Study: 33004133

Group type: EXPERIMENTAL
Intervention: EN-PESA model (Elastic Net model)
Number of subjects: 1411

Group type: EXPERIMENTAL
Intervention: EN-PESA model
Number of subjects: 1411

Group type: COMPARATOR
Intervention: Traditional risk scores (CVD and SCORE)
Number of subjects: 1411
Study: 33004387

Group type: EXPERIMENTAL
Intervention: Women exposed to IPV (n=82)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Women not exposed to IPV (n=41)
Number of subjects: 123
Study: 33004395

Group type: EXPERIMENTAL
Intervention: Family Planning Elevated (FPE) initiative
Number of subjects: 0
Study: 33004541

Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy/ICI combinations
Number of subjects: 0
Study: 33004542

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenous every 3 weeks + Bevacizumab 15 mg/kg intravenous every 3 weeks
Number of subjects: 10
Study: 33004656

Group type: EXPERIMENTAL
Intervention: Local anesthetic volume of 5 mL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Local anesthetic volume of 30-35 mL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Local anesthetic volume (various doses from 5 to 40 mL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Local anesthetic volume (not specified)
Number of subjects: 21
Study: 33004691

Group type: EXPERIMENTAL
Intervention: Recombinant human IGF1 treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: High plasma glucose levels
Number of subjects: 117

Group type: COMPARATOR
Intervention: Oxygen-induced retinopathy plus hyperglycemia/hypoinsulinemia
Number of subjects: 117
Study: 33004905

Group type: EXPERIMENTAL
Intervention: BKM120
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GDC0980
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PI3K inhibition
Number of subjects: 6
Study: 33005039

Group type: EXPERIMENTAL
Intervention: Electric field-optimized, fMRI-guided TMS targeting
Number of subjects: 0
Study: 33005161

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (20 x 2-h sessions of neurocognitive and social-cognitive training, average completion of 12 hours)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 111
Study: 33005432

Group type: EXPERIMENTAL
Intervention: Acupuncture at highly sensitized acupoints
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acupuncture at low/non-sensitized points (control group)
Number of subjects: 36
Study: 33005816

Group type: EXPERIMENTAL
Intervention: Breath stacking technique plus expiratory muscle training (EMT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Breath stacking technique alone
Number of subjects: 42
Study: 33006086

Group type: EXPERIMENTAL
Intervention: Viral-RNA testing
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Universal testing
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Retesting of positive staff (n=33)
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Postponement of procedures for positive cases (n=31)
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Testing of staff due to suspected exposure (n=67)
Number of subjects: 1670
Study: 33006109

Group type: EXPERIMENTAL
Intervention: Diagnosis via NBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnosis via FH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-HSCT management practices
Number of subjects: 0
Study: 33006125

Group type: EXPERIMENTAL
Intervention: MRE values in groups 0-1, N=148
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: High MRE values
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Clinical characteristics across the spectrum of liver stiffness
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Correlation of clinical characteristics with MRE scores
Number of subjects: 194
Study: 33006135

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis (AD)
Number of subjects: 0
Study: 33006561

Group type: EXPERIMENTAL
Intervention: Thrive intervention (iCBT)
Number of subjects: 181
Study: 33006569

Group type: EXPERIMENTAL
Intervention: Smartphone app (Drinks:Ration) with interactive features and personalized messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smartphone app providing only government guidance on alcohol consumption (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smartphone app (Drinks:Ration)
Number of subjects: 0
Study: 33006749

Group type: EXPERIMENTAL
Intervention: Gentle Jogger (GJ)
Number of subjects: 26
Study: 33006765

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 0
Study: 33007136

Group type: EXPERIMENTAL
Intervention: Assessment tool for reusable duodenoscopes
Number of subjects: 1080
Study: 33007265

Group type: EXPERIMENTAL
Intervention: Maternal fecal microbiota transplantation (FMT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (untreated CS-born infants)
Number of subjects: 7
Study: 33007932

Group type: EXPERIMENTAL
Intervention: Various treatment strategies according to local protocols in cardiac centers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive therapy and antithrombotic therapy including patient-tailored strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality-of-life questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33008303

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) defined as GFR < 60, < 45 or < 30 ml/min/1.73 m²
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) stratified by SPPB scores
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Cluster analysis including CKD
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) defined as eGFR < 45 or 30 ml/min/1.73 m²
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Physical performance assessed by SPPB
Number of subjects: 2252
Study: 33008307

Group type: EXPERIMENTAL
Intervention: Lower Urinary Tract Symptoms (LUTS)
Number of subjects: 2256

Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<60
Number of subjects: 2256

Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<45
Number of subjects: 2256

Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<30
Number of subjects: 2256
Study: 33008316

Group type: EXPERIMENTAL
Intervention: HIV-exposed-uninfected (HEU) infants
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Composite primary endpoint
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 1200
Study: 33008359

Group type: EXPERIMENTAL
Intervention: CKD stage 1-2 and 3
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: CKD stage 4
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: All stages of CKD
Number of subjects: 2252
Study: 33008394

Group type: EXPERIMENTAL
Intervention: A-IADL-Q-SV German
Number of subjects: 96
Study: 33008401

Group type: EXPERIMENTAL
Intervention: New estrogen-free contraceptive pill (4 mg drospirenone, 24/4 regimen)
Number of subjects: 2500
Study: 33008407

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffolds (EE-BRS)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 499
Study: 33008435

Group type: EXPERIMENTAL
Intervention: Medication therapy for challenging behavior
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Guided implementation and re-evaluation of specific behavioral measures
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Psychosocial support of MPS-families
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Non-medication approaches
Number of subjects: 34
Study: 33008938

Group type: EXPERIMENTAL
Intervention: Breath volatile organic compounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33009065

Group type: EXPERIMENTAL
Intervention: Non-Celiac Wheat Sensitivity (NCWS)
Number of subjects: 91
Study: 33009222

Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 292

Group type: COMPARATOR
Intervention: Best-corrected visual acuity
Number of subjects: 292
Study: 33010149

Group type: EXPERIMENTAL
Intervention: HCV direct-acting antiviral treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HCV testing
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HCV treatment scale-up
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HCV incidence
Number of subjects: 200
Study: 33010162

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33010231

Group type: EXPERIMENTAL
Intervention: ARI-0001 cells (chimeric antigen receptor T cells targeting CD19)
Number of subjects: 0
Study: 33010459

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg QD plus nivolumab 240 mg every 2 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg QD
Number of subjects: 25
Study: 33010817

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg (cap at 180 mg) and nivolumab at 3 mg/kg, both intravenously every 21 days for 8 cycles
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin and nivolumab
Number of subjects: 46
Study: 33010927

Group type: EXPERIMENTAL
Intervention: Intramuscular tranexamic acid (TXA) 1 g i.v. loading dose followed by two 5 ml (0.5 g each) i.m. injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular tranexamic acid (TXA)
Number of subjects: 30
Study: 33010926

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia (ED group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (non-ED group)
Number of subjects: 60
Study: 33011075

Group type: EXPERIMENTAL
Intervention: ABCB5-ex vivo-expanded mesenchymal stromal cells (MSCs)
Number of subjects: 9
Study: 33011073

Group type: EXPERIMENTAL
Intervention: Magnetic surgical system for liver retraction
Number of subjects: 50
Study: 33011121

Group type: EXPERIMENTAL
Intervention: Lipid-rich plaque
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheroma (TCFA)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Layered plaque
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Macrophage accumulation
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Microvessel presence
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: New layer detected in plaques with rapid progression
Number of subjects: 248
Study: 33011332

Group type: EXPERIMENTAL
Intervention: FIBTEM maximal clot firmness (MCF) at the beginning of surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher haemoglobin concentration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FIBTEM MCF at the end of surgery
Number of subjects: 75
Study: 33011690

Group type: EXPERIMENTAL
Intervention: MINIject supraciliary drainage device implantation
Number of subjects: 25
Study: 33011782

Group type: EXPERIMENTAL
Intervention: Chemotherapy-only treatment (phase 3 trial)
Number of subjects: 233